#United States #Minneapolis #financial results #Bio-Techne #Q3 FY2026

Bio-Techne Corporation Q3 FY2026 Financial Overview

Financial Results Overview

Bio-Techne Corporation (NASDAQ: TECH) has recently shared its financial outcomes for the third quarter ending March 31, 2026. Despite reporting a 2% decline in net sales, totaling $311.4 million, the company showcased resilience in various segments, particularly in the large pharmaceutical sector. The adjustments in revenue were primarily influenced by significant prior-year GMP fast-track orders and timing discrepancies in large Commercial Supply shipments.

Key Highlights:

• - Reported revenue decreased by 2%, both in total and organic terms.
• - GAAP earnings per share (EPS) increased from $0.14 to $0.32, demonstrating an encouraging uptrend in earnings amid challenges.
• - Large pharmaceutical clients marked their sixth consecutive quarter of double-digit growth, contrastingly, spending by emerging biotechnology continues to lag.
• - Stabilization was noted in the U.S. academic markets, which experienced low-single-digit growth.

Segment Performance

Protein Sciences Segment

Focusing on the Protein Sciences segment, which supplies specialized proteins for biopharma and academic research sectors, net sales fell by 1% to $226.2 million. The prevailing market conditions indicate an organic revenue drop of 4% as the segment’s operating margin slightly declined to 44.2%.

Diagnostics and Spatial Biology Segment

The Diagnostics and Spatial Biology segment's net sales experienced a 4% decline to $85.6 million from the previous year, although it achieved a modest 3% organic revenue growth. The operating margin improved to 12.1%, largely due to favorable outcomes from the divestiture of Exosome Diagnostics.

Leadership Insight

Kim Kelderman, President and CEO of Bio-Techne, commented on the mixed market environment, emphasizing the strong execution of the team, especially within the prominent pharmaceutical sector. He noted the ongoing stabilization in U.S. academic demand and expressed optimism regarding the funding activity realignment, which could bolster the company’s outlook in the upcoming quarters.

Financial Metrics Summary

Within the third quarter of fiscal 2026:

• - GAAP Operating Income reached $75.5 million, marking a 95% increase compared to the same quarter last year.
• - Adjusted EPS fell to $0.53, a slight decrease from $0.56, which highlights the impact of tough market dynamics.

Strategic Outlook

Despite the current challenges, Bio-Techne is poised for long-term value creation. The company remains committed to its strategic initiatives aimed at enhancing quality and durability in scientific applications ranging from biological research to precision diagnostics. Kelderman underscored the company's strong operational discipline and financial flexibility as key to navigating market fluctuations.

Earnings Conference Call

Investors and stakeholders are invited to join an earnings conference call hosted by Bio-Techne on May 6, 2026, at 800 a.m. CDT to discuss the financial results and future outlook. The call can be accessed via telephone or live webcast, providing insights for investors seeking detailed information on the company’s financial health and strategic direction.

Conclusion

In closing, while Bio-Techne faces certain revenue challenges, it continues to harness robust growth in vital areas such as large pharmaceuticals and remains focused on strategic innovation and operational excellence. As it adapts to the varying market dynamics, the potential for future growth appears promising.